Khiron Life Sciences

KHRN-V

Analysis and Opinions about KHRN-V

Signal
Opinion
Expert
WATCH
WATCH
November 20, 2019
He got stopped out of this. If you still own it, wait and hold. Cannabis is going through a normal consolidation. Maybe average down during tax-loss selling. He still likes it. Has a $3 target. They're becoming more of a marketing company and getting into pharmaceutical. They're in Colombia where CBD dominates the weed sector which will be a stepping stone to the rest of the world. Also, in Colombia the energy cost is zero.
Show full opinionHide full opinion
He got stopped out of this. If you still own it, wait and hold. Cannabis is going through a normal consolidation. Maybe average down during tax-loss selling. He still likes it. Has a $3 target. They're becoming more of a marketing company and getting into pharmaceutical. They're in Colombia where CBD dominates the weed sector which will be a stepping stone to the rest of the world. Also, in Colombia the energy cost is zero.
TOP PICK
TOP PICK
August 6, 2019
They're weed producers from Colombia where growing weed is easy. Khiron has a great brand in Colombia. Massive sales going into Europe and mostly Latin America. (Analysts’ price target is $6.38)
Show full opinionHide full opinion
They're weed producers from Colombia where growing weed is easy. Khiron has a great brand in Colombia. Massive sales going into Europe and mostly Latin America. (Analysts’ price target is $6.38)
COMMENT
COMMENT
June 19, 2018

They are focused on the medical market in Columbia and more generally in Latin America. They are positioned to be one of the first Columbia-based companies to have product in the domestic market. Their CEO used to manage infrastructure projects for SNC. The other co-founder launched Advil into the country. Another executive has years of experience in the US Drug Enforcement Agency. This is a knowledgeable management team. They plan to replicate their model of doctor engagement throughout South America and Mexico.

Show full opinionHide full opinion

They are focused on the medical market in Columbia and more generally in Latin America. They are positioned to be one of the first Columbia-based companies to have product in the domestic market. Their CEO used to manage infrastructure projects for SNC. The other co-founder launched Advil into the country. Another executive has years of experience in the US Drug Enforcement Agency. This is a knowledgeable management team. They plan to replicate their model of doctor engagement throughout South America and Mexico.

Showing 1 to 3 of 3 entries
  • «
  • 1
  • »